December 10th & 11th, 2026
15th edition
MARSEILLE, FR
Stand C6

2026 Edition

Epics Therapeutics

Belgium

Epics Therapeutics is a Belgian based, clinical-stage drug discovery company that develops small molecules targeting RNA epigenetics and G-Protein Coupled Receptor (GPCR) mechanisms involved in cancer development. By targeting these mechanisms, Epics Therapeutics aims to translate science into life-changing treatments for patients.
Epics Therapeutics’ lead asset is EP102, a METTL3 inhibitor currently in clinical development for the treatment of solid tumors.

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.